Osteoporosis – Epidemiology – Mature Markets
Clarivate Epidemiology's coverage of osteoporosis comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets worldwide. We report the prevalence of osteoporosis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology's osteoporosis forecast will answer the following questions:
- Of all people with osteoporosis, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
- Of all people diagnosed with osteoporosis, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of osteoporosis over the forecast period?
- How will changes in the levels of exposure to known risk or protective factors affect the number of people at high risk for hip fracture or a major osteoporotic fracture?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 20 years of forecast data for the following osteoporosis patient populations:
- Osteoporosis total prevalent cases.
- Total prevalent cases by diagnosis.
- Diagnosed prevalent cases by drug treatment.
Note: coverage may vary by country and region.
Table of contents
- Osteoporosis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Overview
- Total Prevalence of Osteoporosis per 1,000 Among People Aged 40+ in 2021 and 2041
- Relative Sizes of the Contributing Factors to the Trend in Osteoporosis Over the Next 20 Years
- Analysis of the Prevalent Cases of Osteoporosis in 2017 by Diagnosed and Drug-Treated Status
- Epidemiology Data
- Methods
- Total Prevalent Cases
- Total Prevalent Cases: FRAX High Risk
- Diagnosed Prevalent Cases
- Drug-Treated Prevalent Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Osteoporosis
- Studies Excluded from the Analysis of Osteoporosis
- Risk/Protective Factors
- Risk/Protective Factors for Osteoporosis
- Bibliography
- Glossary
- Abbreviations
- Literature Review
- Introduction
Ullas Ulahannan, MPH., Epidemiologist, Epidemiology. Before joining Clarivate, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. His qualifications include a master’s degree in public health from Manipal University, Manipal, and a bachelor’s degree in nursing from Rajiv Gandhi University of Health Sciences, Bangalore
Swarali Tadwalkar, M.P.H., is a principal epidemiologist at Clarivate. Previously, she was involved in primary and secondary healthcare research, including projects in digital health, health policy and management, and health economics and outcomes research (HEOR). Ms. Tadwalkar also coordinated various nongovernmental public health projects focusing on access to treatment for hepatitis and human papilloma virus. She received her M.P.H. from the University of South Florida in Tampa.